65,437 trials
Atopic Dermatitis
Primary: Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (2 mg Baricitinib) — 8.2; 29.5 percentage of participants — p=<0.001
Schizophrenia
Primary: OPC-14597 Plasma Concentration 672 Hours Postdose Following Multiple Administration of OPC-14597 IMD Injections — 91.9; 141; 171; 198 ng/mL
Atopic Dermatitis
Primary: Responder Rate of Investigator's Global Assesment (IGA) of Disease Severity — 44.58; 47.06; 18.07 percentage of participants
Type 2 Diabetes · Type 2 Diabetes Mellitus
Primary: Evaluate the Change In HbA1c Between Groups After 12 Weeks of Treatment. Non-inferiority Hypothesis. — -0.5966; -0.3759 percent — p=0.007
Cancer
Primary: Cancer Detection Performance of FACBC PET/CT — 17; 22; 4; 14 Participants
Opioid Use Disorder, Severe · Opioid Use Disorder, Moderate
Primary: Treatment Emergent Adverse Event (TEAE) Occurrence — 0 Participants
Atrioventricular Block · Ventricular Dysfunction
Primary: Total Mortality — 307; 305 Participants — p=0.3492
Affect
Primary: Change From Baseline Subscales of Mood Survey Scale at 3 Hours — 0.54; -1.27; -2.22 score on a scale
Healthy Volunteers
Primary: Steady State Concentrations of TFV-DP for Different Dosing Patterns of Descovy — 657; 1451; 2381 fmol/punch
Prostate Cancer
Primary: Percentage of Participants With an Immune Response to Prostatic Acid Phosphatase (PAP) and/or PA2024 — 71.4; 87.5 percentage of participants
Atopic Dermatitis
Primary: Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity — 38.46; 12.64 percentage of perticipants
Multiple Myeloma
Primary: Serious Adverse Events — 23; 23; 4; 1 Events
Esophagogastric Adenocarcinoma
Primary: 6-month Progression-free Survival (PFS) — 1.9 months
Stretch Marks · Striae · Treatment
Primary: Width of Stretch Marks — 0.199; 0.146; 0.088; 0.077 centimeters
Chronic Rhinosinusitis (Diagnosis) · Nasal Polyps · Eosinophilia
Primary: Change in Nasal Polyp Score — .9; .3 score on a scale